Awaiting development: Guidance and quality standards

Showing 221 to 230 of 344

Guidance and quality standards awaiting development
Title	Type
Povorcitinib for treating non-segmental vitiligo [GID-TA12019]	Technology appraisal guidance
Povorcitinib for treating prurigo nodularis [GID-TA12018]	Technology appraisal guidance
Pozelimab with cemdisiran for treating symptomatic generalised myasthenia gravis [ID6720]	Technology appraisal guidance
Pridopidine for treating Huntington's disease [ID6525]	Technology appraisal guidance
Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127]	Technology appraisal guidance
PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over [ID1439]	Technology appraisal guidance
Radium-223 dichloride with enzalutamide for treating asymptomatic or mildly symptomatic hormone-relapsed metastatic prostate cancer with bone metastases [ID6512]	Technology appraisal guidance
Ranibizumab port delivery system for treating diabetic macular oedema [ID6137]	Technology appraisal guidance
Ravulizumab for preventing kidney events in people with chronic kidney disease at high risk after a cardiopulmonary bypass [ID6632]	Technology appraisal guidance
Ravulizumab for treating primary IgA nephropathy [ID6703]	Technology appraisal guidance